|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/25/24 Merck & Co., Inc. 8-K:2,9 4/25/24 13:911K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 36K 2: EX-99.1 Miscellaneous Exhibit HTML 337K 3: EX-99.2 Miscellaneous Exhibit HTML 271K 8: R1 Cover HTML 58K 10: XML IDEA XML File -- Filing Summary XML 12K 13: XML XBRL Instance -- tm2412490d1_8k_htm XML 28K 9: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 5: EX-101.DEF XBRL Definitions -- mrk-20240425_def XML 77K 6: EX-101.LAB XBRL Labels -- mrk-20240425_lab XML 107K 7: EX-101.PRE XBRL Presentations -- mrk-20240425_pre XML 74K 4: EX-101.SCH XBRL Schema -- mrk-20240425 XSD 15K 11: JSON XBRL Instance as JSON Data -- MetaLinks 28± 36K 12: ZIP XBRL Zipped Folder -- 0001104659-24-051517-xbrl Zip 66K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 25, 2024 ( i April 25, 2024)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | i 1-6571 (Commission File Number) | (I.R.S. Employer Identification No.) |
i 126 East Lincoln Avenue, i Rahway, i NJ (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code) ( i 908) i 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on April 25, 2024, regarding earnings for the first quarter of 2024, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit 99.1 | Press release issued April 25, 2024, regarding earnings for the first quarter of 2024 |
| Exhibit 99.2 | Certain supplemental information not included in the press release |
| Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Merck & Co., Inc. | ||
| Date: April 25, 2024 | By: | /s/ Kelly E. W. Grez |
Kelly E. W. Grez Corporate Secretary |
||
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 4/25/24 | None on these Dates | ||
| List all Filings | ||||